Metrics as of 10/14/2026, 09:46 AM (Berlin time), refresh in progress.
Actuate Therapeutics Stock
Actuate Therapeutics Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Daniel Schmitt
- Employees
- 12
- Market cap
- $11 M
- IPO
- 13/08/2024
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma.…
Actuate Therapeutics stock: price history
1D
-3.7%
1W
-38.0%
1M
-56.4%
6M
-79.1%
YTD
-92.7%
1Y
-94.4%
2Y
-94.3%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about Actuate Therapeutics
Analyst assessment of Actuate Therapeutics
PRICE TARGET LOW
US$21.00
CONSENSUS
US$21.00
MEDIAN
US$21.00
PRICE TARGET HIGH
US$21.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 18/08/2026
Actuate Therapeutics stock metrics
P/E
-0.51
P/B
10.86
EV/EBITDA
-0.33
RETURN ON EQUITY
-492.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.41
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
35.8%
FLOAT SHARES
8,571,676
AVG. DAILY VOLUME (30D)
331,714
Insider transactions (SEC)
SCHMITT DANIEL M
SCHMITT DANIEL M
Institutional holders
Comparable stocks
Frequently asked questions about Actuate Therapeutics stock
What does Actuate Therapeutics do?
Actuate Therapeutics Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Daniel Schmitt, the company employs around 12 people.
The IPO was on 13/08/2024; the stock trades on NASDAQ under the ticker ACTU.
What do analysts say about Actuate Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
The average price target is US$21.00, ranging from US$21.00 to US$21.00, with a median of US$21.00.
This is an external assessment, not a statement by Market Jury.
When does Actuate Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does Actuate Therapeutics pay a dividend?
No, Actuate Therapeutics currently does not pay a dividend.
Which stocks are comparable to Actuate Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Actuate Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Actuate Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.